Eli Lilly Stock Rises After Profit, Outlook Top Expectations
Eli Lilly stock is higher Thursday after the pharma giant beat fourth-quarter profit expectations and issued strong 2025 guidance. Here's what you need to know.
Eli Lilly (LLY) stock is higher Thursday after the pharmaceutical company beat profit expectations and matched revenue forecasts for its fourth quarter and issued a better-than-expected outlook for 2025.
In the three months ending December 31, Eli Lilly's revenue increased 44.7% year over year to $13.5 billion, driven by demand for its weight-loss drugs, Mounjaro and Zepbound. Earnings per share (EPS) rose 113.7% from the year-ago period to $5.32.
"2024 was a highly successful year for Lilly," said Eli Lilly CEO David Ricks in a statement. In addition to success with its weight-loss drugs, Ricks cited "major data readouts for tirzepatide in treating chronic disease associated with obesity."
From just $107.88 $24.99 for Kiplinger Personal Finance
Become a smarter, better informed investor. Subscribe from just $107.88 $24.99, plus get up to 4 Special Issues
Sign up for Kiplinger’s Free Newsletters
Profit and prosper with the best of expert advice on investing, taxes, retirement, personal finance and more - straight to your e-mail.
Profit and prosper with the best of expert advice - straight to your e-mail.
Eli Lilly also "invested billions more" in its manufacturing capacity and launched Kisunla and Ebglyss. The latter will be "important drivers of our long-term balanced growth outlook," Ricks said. Kisunla is designed to treat early stage Alzheimer's disease, while Ebglyss is for eczema.
The results were mixed compared with analysts' expectations. Wall Street was anticipating revenue of $13.5 billion and earnings of $5.01 per share, according to MarketWatch.
For 2025, Eli Lilly expects to achieve revenue in the range of $58 billion to $61 billion and earnings of $22.50 to $24 per share. The midpoints of these ranges, revenue of $59.5 billion and earnings of $23.25 per share, came in ahead of analysts' expectations of revenue of $58.8 billion and earnings of $22.76 per share.
"We enter 2025 with tremendous momentum and look forward to strong financial performance and several important Phase 3 readouts which, if positive, will further accelerate our long-term growth," Ricks said.
That should support the drug maker's quarterly payout to shareholders as well. Eli Lilly's long track record makes it one of Wall Street's best dividend stock.
Competition in the weight-loss drug category with Novo Nordisk (NVO) and its Ozempic continues to define Eli Lilly's results. A recent Food and Drug Administration clarification of the tirzepatide shortage should help both LLY and NVO.
Is Eli Lilly stock a buy, sell or hold?
LLY tumbled 6.6% on January 14 after management pre-announced fourth-quarter results. Sales for Mounjaro and Zepbound met expectations set in mid-January, and Wall Street sees further upside for the healthcare stock.
According to S&P Global Market Intelligence, the consensus analyst target price for LLY stock is $975.09, representing implied upside of about 14% to current levels. And the consensus recommendation is Buy.
Financial services firm Jefferies has a Buy rating on the large-cap stock with a $994 price target.
"We're bullish on LLY for several reasons," Jefferies analyst Akash Tewari said in a December 19 note, citing Eli Lilly's attractive growth profile in a recessionary environment and the potential for GLP-1s to be among the biggest drug classes of all time.
The analyst also sees near-term upside for both revenue and EPS growth.
Related Content
-
7 Ways to Kick Off an Estate Planning Talk With Your ParentsIt can be hard for aging parents to discuss estate plans — and for adult kids to broach the topic. Here are seven questions to get the conversation started
-
4 Reasons Why the Dollar Remains the World HeavyweightThe dollar may have taken a beating lately, but it's unlikely to be overtaken as the leading reserve currency any time soon. What's behind its staying power?
-
The Top 10 Side Gigs For Retirees In 2026Money is freedom in retirement; here’s how to earn more of it with a profitable side gig
-
7 Questions to Help Kick Off an Estate Planning Talk With Your Parents
It can be hard for aging parents to discuss estate plans — and for adult kids to broach the topic. Here are seven questions to get the conversation started
-
Down But Not Out: 4 Reasons Why the Dollar Remains the World Heavyweight
The dollar may have taken a beating lately, but it's unlikely to be overtaken as the leading reserve currency any time soon. What's behind its staying power?
-
What Not to Do After Inheriting Wealth: 4 Mistakes That Could Cost You EverythingGen X and Millennials are expected to receive trillions of dollars in inheritance. Unless it's managed properly, the money could slip through their fingers.
-
'The Money Prism' Solves Retirement Money's Biggest Headache: Here's HowThis simple, three-zone system (Blue for bills, Green for paycheck, Red for growth) helps you organize your retirement savings by purpose and time.
-
No, AI Can't Plan Your Retirement: This (Human) Investment Adviser Explains WhyAI has infinite uses. But creating an accurate retirement strategy based on your unique goals is one place where its possibilities seem lacking.
-
A Value Focus Clips Returns for This Mairs & Power Growth FundRough years for UnitedHealth and Fiserv have weighed on returns for one of our favorite mutual funds.
-
Small-Cap Stocks Gain Momentum. That's Good News for This iShares ETFThe clouds appear to be parting for small-cap stocks, which bodes well for one of our favorite exchange-traded funds.
-
Don't Let a 60/40 Portfolio Derail Your Retirement: Why a Cookie-Cutter Approach Could Cost YouChoosing a personalized retirement investment plan, rather than relying on the 60/40 portfolio, could help protect your savings and ensure long-term growth.
